EGFR Exon 20 Insertion: A New Player in the NSCLC Landscape
October 13, 2021
The success of precision medicine relies on choosing the right targeted therapy for each patient. However, these therapeutic decisions depend on careful, effective molecular profiling. How to best address clinically relevant biomarker status? What technology should we use? Developments in lung cancer management may provide answers. Here, Luca Quagliata (Vice-President and Global Head of Medical Affairs, Clinical NGS and Oncology Division, Thermo Fisher Scientific) speaks to Parthiv Mahadevia (Senior Global Medical Affairs Leader, Janssen R&D).
1 min read